InspireMD (STU:II2) Institutional Ownership: 4.52% (As of Jul. 11, 2026)


STU:II2 InspireMD Inc STU:II2
41 GF Score
Price €0.63
GF Value €1.50
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD Institutional Ownership?

InspireMD STU:II2 +2.46% 41 Institutional Ownership is 4.52% as of Jul. 11, 2026. GuruFocus rates STU:II2 with a GF Score™ of 41/100 and a GF Value™ of €1.50 (Possible Value Trap). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, InspireMD's institutional ownership is 4.52%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, InspireMD's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, InspireMD's Float Percentage Of Total Shares Outstanding is 94.05%.

InspireMD Institutional Ownership Historical Data

* Premium members only.

The historical data trend for InspireMD's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InspireMD Institutional Ownership Chart

InspireMD Historical Data

The historical data trend for InspireMD can be seen below:

2025-08-31 2025-09-30 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 3.19 3.18 4.11 4.08 4.10 4.09 4.12 3.83 4.44 4.52
STU:II2
41GF Score
InspireMD Inc STU:II2
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InspireMD Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 4.52% mean?
InspireMD (STU:II2) has a Institutional Ownership of 4.52% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on InspireMD and its competitors.
Is InspireMD's Institutional Ownership too high?
InspireMD's current Institutional Ownership is 4.52%. Overall, InspireMD has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Institutional Ownership compare to TELA and BDMD?
InspireMD's Institutional Ownership of 4.52% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Devices & Instruments company?
A good Institutional Ownership depends on the Medical Devices & Instruments industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on InspireMD and its competitors. InspireMD's current Institutional Ownership is 4.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.50, compared to a current price of €0.63 — trading 58.3% below its estimated fair value. The current Institutional Ownership is 4.52%. InspireMD's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For InspireMD (STU:II2), the current Institutional Ownership is 4.52% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.63 is trading 58.3% below its estimated GF Value™ of €1.50. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • Institutional Ownership: 4.52%
  • GF Value™: €1.50 vs. price of €0.63 (58.3% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
41GF Score

Get the complete analysis for STU:II2

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.63
Price
€1.50
GF Value